Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.72 |
| ▸ | HPGD | P15428 | 7/20 | 0.72 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | CA12 | O43570 | 1/20 | 0.72 |
| ▸ | CA1 | P00915 | 1/20 | 0.72 |
| ▸ | CA2 | P00918 | 1/20 | 0.72 |
| ▸ | CA4 | P22748 | 1/20 | 0.72 |
| ▸ | CA6 | P23280 | 1/20 | 0.72 |
| ▸ | CA7 | P43166 | 1/20 | 0.72 |
| ▸ | CA9 | Q16790 | 1/20 | 0.72 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.72 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | G6PD | P11413 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL7085411 | 1.00 | KDM4E (0.72) | KDM4EALDH1A1HPGDHMGB1SMN1; SMN2 | |
| Salicylic Acid SCHEMBL1835791 | 1.00 | KDM4E (0.72) | KDM4EALDH1A1HPGDHMGB1SMN1; SMN2 | |
| Salicylic Acid SCHEMBL5195824 | 1.00 | KDM4E (0.72) | KDM4EALDH1A1HPGDHMGB1SMN1; SMN2 | |
| Salicylic Acid SCHEMBL2450905 | 0.92 | ALDH1A1 (0.78) | KDM4EALDH1A1HPGDHMGB1SMN1; SMN2 | |
| Salicylic Acid SCHEMBL31230843 | 0.92 | ALDH1A1 (0.78) | KDM4EALDH1A1HPGDHMGB1SMN1; SMN2 | |
| Salicylic Acid SCHEMBL30340746 | 0.92 | ALDH1A1 (0.78) | KDM4EALDH1A1HPGDHMGB1SMN1; SMN2 | |
| Salicylic Acid SCHEMBL11590105 | 0.92 | ALDH1A1 (0.78) | KDM4EALDH1A1HPGDHMGB1SMN1; SMN2 | |
| Salicylic Acid SCHEMBL28399898 | 0.92 | ALDH1A1 (0.78) | KDM4EALDH1A1HPGDHMGB1SMN1; SMN2 | |
| Salicylic Acid SCHEMBL11512229 | 0.90 | ALDH1A1 (0.75) | KDM4EALDH1A1HPGDHMGB1SMN1; SMN2 | |
| Salicylic Acid SCHEMBL6063018 | 0.90 | KDM4E (0.82) | KDM4EALDH1A1HPGDHMGB1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7597881-B2 | Use of ester quats in compositions as sand-repellent substances | GOLDSCHMIDT GMBH (DE) | 2009-10-06 | — | — | US | disclosed |
| US-20080193393-A1 | Delivery System for Topically Applied Compounds | LIPO CHEMICALS INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20070231289-A1 | Use of ester quats in compositions as sand-repellent substances | GOLDSCHMIDT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-6528070-B1 | Emulsification system comprising a mixture of at least one cationic surfactant, at least one anionic surfactant, at least one \"bridging surfactant\", an oil and water, along with methods for preparing such emulsions. Synergistic mixtures of | STEPAN COMPANY | 2003-03-04 | — | — | US | disclosed |
| EP-0814760-B1 | SUBSTITUTED o-AMINOCARBONYLBENZOIC ACID SALTS AND THEIR USE AS SUNSCREENS | STEPAN CO (US) | 2000-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231289-A1 | Use of ester quats in compositions as sand-repellent substances | CUTA, DLAT, CRAT | KDM4E 692/4885ALDH1A1 224/4885HPGD 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.